Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Hers vs Lean Meds

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Hers logo

Hers

6.6
★★★☆☆3.3/5

Best for: coverage in all 50 states, which most of the register will not confirm

Visit Hers
VS
Lean Meds logo

Lean Meds

9.3
★★★★4.7/5

Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy

Visit Lean Meds

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, Lean Meds opens cheaper — $79/mo against $199, and Lean Meds finishes ahead, 9.3 to 6.6. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

Hers

StartingCompounded
$199/mo
semaglutide
StartingBrand-name
$299/mo
tirzepatide

Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)

Lean Meds

Any dose, month-to-month (same price at every dose)Compounded
$79/mo
semaglutide

Standing month-to-month rate. The advertised $69 is the 12-month prepay tier; 3-month is $76 and 6-month is $73.

Any dose, month-to-month (same price at every dose)Compounded
$109/mo
tirzepatide

Standing month-to-month rate. Prepay tiers: $105 for 3 months, $100 for 6, $95 for 12.

What’s included

Hers

Covered by the monthly price

Medication

In the price

Clinician visits

Charged on top

Shipping

Not stated

Lab work

Not stated

Coaching

Charged on top

Lean Meds

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

Hers

6.6/10

Overall

Lean Meds

9.3/10

Value25%

3.0A
vs
B
10.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

5.5A
vs
B
9.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

3.0A
vs
B
7.0

Features & Coverage

FeatureHersLean Meds
Starting Price$199/mo$79/mo
Features2 features7 features
States Available5050
Compounded✓ Yes✓ Yes
Brand Name✓ Yes
FSA/HSA Accepted
FDA Warnings1 warningNone

About Hers

Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.

Read our full Hers review →

About Lean Meds

Titrating up does not raise the rate, which is flat and monthly: $79 to start on compounded semaglutide, $109 on compounded tirzepatide, the telehealth visit and shipping absorbed into both. Clinicians come from the OpenLoop Health network. Trinity HealthCare Supply, LLC operates the service and puts names to its five dispensing pharmacies as well as to the physicians who prescribe.

Read our full Lean Meds review →

Pros & Cons

Hers

What we like

  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly figure covers medication
  • Coverage is published for all 50 states

Watch-outs

  • Billed separately from the monthly figure: consult, coaching
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
  • 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
  • Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality

Lean Meds

What we like

  • Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
  • Tirzepatide at $109 a month, 59% below the $267 median for the same drug and form across this register
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
  • The monthly figure covers medication, consult, shipping
  • Coverage is published for all 50 states
  • Names 5 dispensing pharmacies, which most sellers in this register do not do
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Lean Meds

Lean Meds takes it, 9.3 against 6.6, and it is especially strong on knowing which pharmacy fills the vial — it names Belmar Pharmacy. Hers is no weak second and may fit you better on coverage in all 50 states, which most of the register will not confirm.

Choose Hers if…

You want coverage in all 50 states, which most of the register will not confirm and an opening price near $199 a month.

Choose Lean Meds if…

You want knowing which pharmacy fills the vial — it names Belmar Pharmacy and an opening price near $79 a month.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.8

Gala

Moving between compounded and brand without changing seller

9.4

Trimi Health

Knowing which pharmacy fills the vial — it names VialsRx

8.5

Strut Health

Semaglutide at $99/month, 48% under the register median

Hers vs Lean Meds: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring Hers and Lean Meds head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.